FDA Makes It Official With Basaglar Approval For Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
Eli Lilly/Boehringer Ingelheim’s insulin glargine product had already received tentative approval from FDA. The final approval clears the way for an eventual copycat version of Sanofi’s Lantus.
You may also be interested in...
Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars
The company will not commercialize an insulin glargine copy already tentatively approved by FDA as Lusduna, but says it remains committed to biosimilars in oncology and immunology.
Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars
The company will not commercialize an insulin glargine copy already tentatively approved by FDA as Lusduna, but says it remains committed to biosimilars in oncology and immunology.
Biologics Transition Plan From US FDA Will Consider Therapeutic Equivalence Ratings
While industry awaits formal guidance ahead of March 2020 transition deadline for certain protein products, FDA's Christl says plan will take into account therapeutic equivalence ratings when deciding whether products are 'deemed' licensed as full biologic applications or biosimilars.